Your browser doesn't support javascript.
loading
Serum uric acid as a surrogate marker of favorable response to bevacizumab treatment in patients with metastatic colon cancer.
Selcukbiricik, F; Kanbay, M; Solak, Y; Bilici, A; Kanitez, M; Balik, E; Mandel, N M.
Afiliação
  • Selcukbiricik F; Department of Medical Oncology, Faculty of Medicine, Koc University, Istanbul, Turkey. fsbiricik@yahoo.com.
  • Kanbay M; Department of Nephrology, Faculty of Medicine, Koc University, Istanbul, Turkey.
  • Solak Y; Department of Nephrology, Sakarya Education and Research Hospital, Korucuk, Turkey.
  • Bilici A; Department of Medical Oncology, Faculty of Medicine, Medipol University, Istanbul, Turkey.
  • Kanitez M; Department of Medical Oncology, Hamidiye Sisli Education and Research Hospital, Istanbul, Turkey.
  • Balik E; Department of General Surgery, Faculty of Medicine, Koc University, Istanbul, Turkey.
  • Mandel NM; Department of Medical Oncology, Faculty of Medicine, Koc University, Istanbul, Turkey.
Clin Transl Oncol ; 18(11): 1082-1087, 2016 Nov.
Article em En | MEDLINE | ID: mdl-26781472
Bevacizumab is a monoclonal antibody which is a vascular endothelial growth factor inhibitor. It obscures vascularization of tumor tissue and damages intratumoral microcirculation. The damaged intratumoral microcirculation leads to tissue hypoxia and results in increase of uric acid level. The main aim of our study was to investigate the relationship between uric acid change and response to bevacizumab therapy. This study included a total of 158 patients with metastatic colorectal cancer who had received bevacizumab therapy. The number of male patients was 100 (63.3 %) while female patients number was 58 (37.7 %). The median age was 61 (29-83). There was relationship between increase of uric acid level of third month uric acid level and stable disease (p < 0.001). There was a significant overall survival increased in the group with increased uric acid level (p < 0.001). The decline of CEA level was related to uric acid level (p < 0.022). In conclusion, this study is the first showing significant increases of serum uric acid in patients with metastatic colorectal cancer who favorably responded to chemotherapy with bevacizumab. But further studies are justified to test whether monitoring uric acid levels might predict clinical outcomes of patients with metastatic colorectal cancer.
Assuntos
Palavras-chave
Buscar no Google
Adicionar na Minha BVS
Imprimir
XML
PubMed Links

Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Ácido Úrico / Protocolos de Quimioterapia Combinada Antineoplásica / Biomarcadores Tumorais / Neoplasias do Colo / Bevacizumab Tipo de estudo: Etiology_studies / Incidence_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Revista: Clin Transl Oncol Ano de publicação: 2016 Tipo de documento: Article País de afiliação: Turquia País de publicação: Itália
Buscar no Google
Adicionar na Minha BVS
Imprimir
XML
PubMed Links

Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Ácido Úrico / Protocolos de Quimioterapia Combinada Antineoplásica / Biomarcadores Tumorais / Neoplasias do Colo / Bevacizumab Tipo de estudo: Etiology_studies / Incidence_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Revista: Clin Transl Oncol Ano de publicação: 2016 Tipo de documento: Article País de afiliação: Turquia País de publicação: Itália